Insulin-like growth factor (IGF)-I, IGF binding protein-3, and prostate cancer: correlation with Gleason score.
BACKGROUND
Non-androgenic growth factors are involved in the growth regulation of prostate cancer (PCa).


OBJECTIVE
This is the first Brazilian study to correlate, in a population of patients operated for PCa, PSA, total testosterone, insulin-like growth factor-I (IGF-I) and insulin-like growth factor-binding protein-3 (IGFBP-3) with Gleason score and to compare with a control group with benign prostate hyperplasia (BPH).


METHODS
This retrospective single-center study included 49 men with previously diagnosed PCa and 45 with previously diagnosed BPH. PSA, testosterone, IGF-I, IGFBP-3 were determined in both groups.


RESULTS
PSA and IGFBP-3 levels were significantly higher in the PCa group as compared to the BPH group (p < 0.001 and p=0.004, respectively). There was a significant difference when we compared the PSA before surgery (p < 0.001) and at the inclusion in the study (p < 0.001) and IGFBP3 (0.016) among patients with Gleason < 7, ≥7 and BPH. In the PCa group, PSA, testosterone, IGF-I and IGFBP-3 levels were comparable between Gleason < 7 and ≥7.


CONCLUSIONS
Our data suggest that in localized PCa, the quantification of PSA and, not of IGF-1, may provide independent significant information in the aggressiveness. IGFBP-3 could be a biochemical marker of disease control in PCa patients.
Endocrinology Service, University Hospital Clementino Fraga Filho (HUCFF), Universidade Federal do Rio de Janeiro, RJ, Brazil.|Instituto Estadual de Diabetes e Endocrinologia Luiz Capriglione (IEDE), Rio de Janeiro, RJ, Brazil.
Livia L
LL
Correa
Endocrinology Service, University Hospital Clementino Fraga Filho (HUCFF), Universidade Federal do Rio de Janeiro, RJ, Brazil.|Endocrinology Service, Hospital Federal da Lagoa, Rio de Janeiro, RJ, Brazil.
Leonardo Vieira
LV
Neto
Endocrinology Service, University Hospital Clementino Fraga Filho (HUCFF), Universidade Federal do Rio de Janeiro, RJ, Brazil.|Endocrinology Service, University Hospital Antônio Pedro (HUAP), Universidade Federal Fluminense (UFF), Niterói, RJ, Brazil.
Giovanna A Balarini
GA
Lima
Urology Service, University Hospital Clementino Fraga Filho (HUCFF), Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil.
Rafael
R
Gabrich
Urology Service, University Hospital Clementino Fraga Filho (HUCFF), Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil.
Luiz Carlos D de
LC
Miranda
Endocrinology Service, University Hospital Clementino Fraga Filho (HUCFF), Universidade Federal do Rio de Janeiro, RJ, Brazil.
Monica R
MR
Gadelha
D000230:Adenocarcinoma / Q000097:blood / Q000473:pathology*; D000368:Aged; D014408:Biomarkers, Tumor; D006801:Humans; D018972:Insulin-Like Growth Factor Binding Protein 3 / Q000097:blood*; D007334:Insulin-Like Growth Factor I / Q000032:analysis*; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D017430:Prostate-Specific Antigen / Q000097:blood*; D011470:Prostatic Hyperplasia / Q000097:blood / Q000473:pathology*; D011471:Prostatic Neoplasms / Q000097:blood / Q000473:pathology*; D012016:Reference Values; D012189:Retrospective Studies; D012307:Risk Factors; D018709:Statistics, Nonparametric; D013739:Testosterone / Q000097:blood*
D014408:Biomarkers, Tumor; D018972:Insulin-Like Growth Factor Binding Protein 3; D013739:Testosterone; D007334:Insulin-Like Growth Factor I; D017430:Prostate-Specific Antigen